Ouverture: | - |
Variation: | - |
Volume: | - |
+ Bas: | - |
+ Haut: | - |
Ecart + Bas / + Haut: | - |
Type: | Actions |
Ticker: | BB |
ISIN: | CH0038389992 |
DGAP-Adhoc: BB Biotech AG publishes its interim report
- 69
DGAP-Ad-hoc: BB BIOTECH AG / Mot-clé(s) : Rapport intermédiaire Media release of July 24, 2020 Interim report of BB Biotech AG as at June 30, 2020 BB Biotech AG publishes its interim report Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2020 amounted to CHF 422 mn (profit of CHF 554 mn in H1 2019). In the second quarter a profit of CHF 1'180 mn (loss of CHF 336 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG's interim report as at June 30, 2020 can be downloaded at www.bbbiotech.com.
Company profile Disclaimer
24.07.2020 CET/CEST Communiqué de presse transmis par Tensid EQS AG. www.eqs.com |
Langue : | Français |
Entreprise : | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Schweiz | |
Téléphone : | +41 52 624 08 45 |
E-mail : | [email protected] |
Site internet : | www.bbbiotech.ch |
ISIN : | CH0038389992 |
Numéro valeur : | A0NFN3 |
Bourses : | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; SIX |
EQS News ID : | 1100723 |
Fin du message | DGAP News-Service |
|
1100723 24.07.2020 CET/CEST
EQS Group est un leader mondial de solutions digitales pour la communication financière et corporate et la compliance. Plus de 8 000 sociétés dans le monde font confiance aux services d’EQS Group pour s’adresser de façon efficace et sécurisée à une audience nationale et internationale de partenaires et pour se conformer aux directives et obligations réglementaires.